Claude Pellen

Claude Pellen

Auto-generated profile, based on publicly available information

Claude Pellen

Comité National de Coordination de la Recherche

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
FNFlorian Naudet
Florian Naudet
MSMaximilian Siebert
Maximilian Siebert
CPClaude Pellen
Claude Pellen
JGJeanne Gaba
Jeanne Gaba
CACathrine Axfors
Cathrine Axfors
JIJohn P. A. Ioannidis
John P. A. Ioannidis
Florian Naudet and co-authors discuss strengthening requirements for sharing clinical trial data.

9 March 2023 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
CPClaude Pellen
Claude Pellen
ALAnne Le Louarn
Anne Le Louarn
GSGilliosa Spurrier-Bernard
Gilliosa Spurrier-Bernard
EDEvelyne Decullier
Evelyne Decullier
JCJean-Marie Chrétien
Jean-Marie Chrétien
FNFlorian Naudet
Florian Naudet
Clinical trial data-sharing is seen as an imperative for research integrity and is becoming increasingly encouraged or even required by funders, journals, and other stakeholders. However, early experiences with data-sharing have been disappointing because they are not always conducted properly. Health data is indeed sensitive and not always easy to share in a responsible way. We propose 10 rules for researchers wishing to share their data. These rules cover the majority of elements to be considered in order to start the commendable process of clinical trial data-sharing: Rule 1: Abide by local legal and regulatory data protection requirements Rule 2: Anticipate the possibility of clinical trial data-sharing before obtaining funding Rule 3: Declare your intent to share data in the registration step Rule 4: Involve research participants Rule 5: Determine the method of data access Rule 6: Remember there are several other elements to share Rule 7: Do not proceed alone Rule 8: Deploy optimal data management to ensure that the data shared is useful Rule 9: Minimize risks Rule 10: Strive for excellence.

20 January 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
CPClaude Pellen
Claude Pellen
NMNchangwi Syntia Munung
Nchangwi Syntia Munung
AAAnna Catharina Armond
Anna Catharina Armond
DKDaniel Kulp
Daniel Kulp
UMUlrich Mansmann
Ulrich Mansmann
FNFlorian Naudet
Florian Naudet
Guided by the FAIR principles (Findable, Accessible, Interoperable, Reusable), responsible data sharing requires well-organized, high-quality datasets. However, researchers often struggle with implementing Data Management and Sharing Plans due to lack of knowledge on how to do this, time constraints, and legal, technical, and financial challenges, particularly concerning data ownership and privacy. While patients support data sharing, researchers and funders may hesitate, fearing the loss of intellectual property or competitive advantage. Although some journals and institutions encourage or mandate data sharing, further progress is needed. Additionally, global solutions are vital to ensure equitable participation from low- and middle-income countries. Ultimately, responsible data sharing requires strategic planning, cultural shifts in research, and coordinated efforts from all stakeholders to become standard practice in biomedical research.

28 November 2025 in BMC Medicine
Verified
Journal Article
Open access
PDF file
FNFlorian Naudet
Florian Naudet
CPClaude Pellen
Claude Pellen
LFLiviu A. - Liviu-Andrei Fodor
Liviu A. - Liviu-Andrei Fodor
CGChiara Gastaldon
Chiara Gastaldon
CBCorrado Barbui
Corrado Barbui
ICIoana A. Cristea
Ioana A. Cristea
In 2019, the FDA and EMA approved intranasal esketamine for treatment-resistant depression (TRD). The current study re-evaluated its efficacy and safety. T

1 September 2021 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
CPClaude Pellen
Claude Pellen
LCLaura Caquelin
Laura Caquelin
ABAlexia Jouvance-Le Bail
Alexia Jouvance-Le Bail
JGJeanne Gaba
Jeanne Gaba
MVMathilde Vérin
Mathilde Vérin
FNFlorian Naudet
Florian Naudet

6 June 2021 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
NAN. Anthony
N. Anthony
CPC. Pellen
C. Pellen
COC. Ohmann
C. Ohmann
DMDavid Moher
David Moher
FNF. Naudet
F. Naudet
Background: Data-sharing policies in randomized clinical trials (RCTs) should have an evaluation component. The main objective of this case–control study was to assess the impact of published re-uses of RCT data in terms of media attention (Altmetric) and citation rates. Methods: Re-uses of RCT data published up to December 2019 (cases) were searched for by two reviewers on 3 repositories (CSDR, YODA project, and Vivli) and matched to control papers published in the same journal. The Altmetric Attention Score (primary outcome), components of this score (e.g. mention of policy sources, media attention) and the total number of citations were compared between these two groups. Results: 89 re-uses were identified: 48 (53.9%) secondary analyses, 34 (38.2%) meta-analyses, 4 (4.5%) methodological analyses and 3 (3.4%) re-analyses. The median (interquartile range) Altmetric Attention Scores were 5.9 (1.3—22.2) for re-use and 2.8 (0.3—12.3) for controls (p = 0.14). No statistical difference was found on any of the components of in the Altmetric Attention Score. The median (interquartile range) numbers of citations were 3 (1—8) for reuses and 4 (1 – 11.5) for controls (p = 0.30). Only 6/89 re-uses (6.7%) were cited in a policy source. Conclusions: Using all available re-uses of RCT data to date from major data repositories, we were not able to demonstrate that re-uses attracted more attention than a matched sample of studies published in the same journals. Small average differences are still possible, as the sample size was limited. However matching choices have some limitations so results should be interpreted very cautiously. Also, citations by policy sources for re-uses were rare. Trial registration: Registration: osf.io/fp62e